2 Department of Biochemistry & Molecular Biology, School of Biomedical Sciences, Monash University, Clayton, 3800, Australia
3 Department of Anatomy & Developmental Biology, School of Biomedical Sciences, Monash University, Clayton, 3800, Australia
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Since the beginning of the 20th century there has been a decline in the reproductive vitality of men within the Western world. The declining sperm quantity and quality has been associated with increased overt disorders of sexual development including hypospadias, undescended testes and type II testicular germ cell tumours (TGCTs). The increase in TGCTs cannot be accounted for by genetic changes in the population. Therefore exposure to environmental toxicants appears to be a major contributor to the aetiology of TGCTs and men with a genetic predisposition are particularly vulnerable. In particular, Type II TGCTs have been identified to arise from a precursor lesion Carcinoma in situ (CIS), identified as a dysfunctional gonocyte; however, the exact triggers for CIS development are currently unknown. Therefore the transition from gonocytes into spermatogonia is key to those studying TGCTs. Recently we have identified seven miRNA molecules (including members of the miR-290 family and miR-136, 463* and 743a) to be significantly changed over this transition period. These miRNA molecules are predicted to have targets within the CXCR4, PTEN, DHH, RAC and PDGF pathways, all of which have important roles in germ cell migration, proliferation and homing to the spermatogonial stem cell niche. Given the plethora of potential targets affected by each miRNA molecule, subtle changes in miRNA expression could have significant consequences e.g. tumourigenesis. The role of non-traditional oncogenes and tumour suppressors such as miRNA in TGCT is highlighted by the fact that the majority of these tumours express wild type p53, a pivotal tumour suppressor usually inactivated in cancer. While treatment of TGCTs is highly successful, the impact of these treatments on fertility means that identification of exact triggers, earlier diagnosis and alternate treatments are essential. This review examines the genetic factors and possible triggers of type II TGCT to highlight target areas for potential new treatments.
Testicular cancers are generally grouped into three broad categories with type I testicular germ cell tumours (TGCTs) being observed primarily in neonatal boys and young children and consisting of benign teratomas and malignant yolk sac tumours1. Type III TGCT, also called spermatocytic seminomas, affect older men above 50 years of age and are derived from a slow growing expansion of type B spermatogonia2. Type II TGCTs mostly affect men aged between 20 and 40; however, the origins of this tumour type are much earlier during foetal development3. All type II TGCTs develop from a pre-invasive lesion termed Carcinoma in situ (CIS), which has been identified as a dysfunctional foetal germ cell2,4.
In the developed world the incidence of type II TGCT (seminoma and non-seminoma), but not type I or II, has increased significantly over the last century to become the most common malignancy found in men aged between 20 and 40 years of age5–7. Such findings have led to speculation that environmental factors impact on the tumorigenesis of this cancer8. In addition, several genetic mutations have been discovered that positively impact TGCT rates in both sporadic and familial cases of TGCTs8,9. While the characterisation of risk factors is far from being completed, one of the most promising indicators of TGCT is mutations in c-KIT and KIT ligand10–13.
The perceived association of TGCTs with infertility combined with evidence that pre-existing subfertility increases in patients with type II tumours, raises the possibility that these lesions may act as indicators of a general reduction in male reproductive health and rising fertility problems within the male population14,15. Type II TGCT is known to develop from dysfunctional gonocytes located within the seminiferous tubules16, indicating that the risk factors predisposing an individual to TGCTs are active early in male foetal development, necessitating the investigation of early germ cell development in an effort to identify causative factors for type II TGCTs. In this review we examine normal germ cell development and potential areas of this differentiation that are modified during the development of type II TGCTs. We also discuss the genetic and environmental contributions to disease specification as well as risk factors and indicators of tumour progression.
Germ cell development
Germ cell specification
Primordial germ cells (PGCs) are signalled to develop by Bone Morphogenic proteins (BMPs) secreted from the extraembryonic ectoderm and the visceral endoderm17. BMPs (BMP4, BMP2, and BMP8b), in turn activate the expression of Fragilis (IFITMS) genes17,18. In the mouse around six of the Fragilis positive cells begin to express BLIMP1/PRDM1 and PRDM14 at embryonic day (E) 6.5 and thereafter are committed to the germ line (Figure 1)19–23. BLIMP1 is a key component of germ cell specification as studies of the BLIMP1 knockout mouse have revealed that PGCs cluster, but fail to migrate24. The expression of BLIMP represses the expression of somatic genes such as HOX, FDF8 and SNAIL, in addition to DNA methyl transferases25. The combination of the highly proliferative nature of the germ cells i.e. expansion from six cells at E6.5, to 250 cells at E9.5, 1000 cells at E10.5, and 26,000 cells at E13.5, and the lack of maintenance DNA methyltransferases causes general demethylation of the DNA in primordial germ cells25,26. The methylation status, and the repression of somatic cell phenotype, permits the expression of pluripotency factors such as NANOG and OCT 3/4 (but not c-MYC and KLF - required for total pluripotency)26. SOX2, an essential pluripotency factor in mouse, is not expressed in human primordial germ cells. However, it is expressed in nonseminoma germ cell tumours26.
OCT 3/4 is expressed in pluripotent cells of the inner cell mass of a blastocyst and, in contrast to the differentiating somatic cells, its expression is maintained in primordial germ cells17,27. OCT 3/4 is believed to control primordial germ cell survival, given that germ cells are lost through an apoptotic pathway in OCT 3/4 null mice17,28. In mice, SOX2 acts in conjunction with OCT 3/4 and its expression is maintained in primordial germ cells until they migrate, colonise the gonad, and become specified as pre-spermatogonia or oogonia, whereupon SOX2 is down regulated17,29. The pattern of NANOG expression tracks that of SOX2, and is required for the maturation of germ cells once they reach the genital ridges17,30. The exact roles of OCT 3/4, SOX2 and NANOG in primordial germ cells is currently unknown, but as they are important for maintaining pluripotency and proliferation in embryonic stem (ES) cells, it is considered likely that they also maintain pluripotency in germ cells and prevent their differentiation17. More recently, several other pluripotency factors have been identified in primordial germ cells, gonocytes and pre-spermatogonia20. One such protein is LIN28, which is involved in maintaining pluripotency and survival. LIN28 is located upstream of, but linked to, both OCT 3/4 and NANOG expression. Additionally LIN28 is not found in postnatal spermatogonia but is expressed in CIS, seminoma, and embryonal carcinoma, further demonstrating the importance of the differentiation of germ cells to maintain normal testis development20,31. Another pluripotency protein identified upstream of the classical pluripotency regulator OCT 3/4, and capable of interacting with NANOG, is SALL432. SALL4 is expressed late primordial germ cells, pre-spermatogonia, and spermatogonial stem cells and is hypothesised to be involved in both the maintenance of primordial germ cells as well as the differentiation of spermatogonial stem cells32,33.
Primordial germ cells and pluripotency
Interestingly, primordial germ cells are not natively pluripotent. Indeed, despite the fact that they express many pluripotency markers, they only differentiate into one cell type i.e. a germ cell26. However, pluripotency can be induced in in vitro cultures of germ cells, if they are isolated before the colonisation of the gonad and incubated in the presence of the growth factors SCF, FGF2, and LIF17. In addition, germ cells are more efficiently transformed into pluripotent cells in the presence of FFG2 in conjunction with MAK2k and GSK3B, as well as TGFB type 1 receptor inhibitors34.
Germ cell maintenance
Once primordial germ cells are specified, germ cell specific genes that promote cell survival, such as STELLA and NANOS3, are up-regulated (Figure 1)17. Other markers of primordial germ cells include SSEA1, PRDM14, DND1, Fragilis, LIN28, c-KIT and MVH26. DND (dead end/Ter) prevents miRNA mediated translational repression and serves as a survival factor for PGCs. Mutations in DND cause testicular teratomas and DND null mice lose their PGCs via apoptosis between E8.5 and E12.59. At E7.5 in the mouse (3 weeks in humans) PLAP (Placental Like Alkaline Phosphatase)-positive PGCs reside in the posterior of the primitive streak and become motile shortly after this time35,36.
Germ cell migration
Primordial germ cells initially migrate into the hindgut during its anterior extension (E8-9.5); they then move into the mesoderm (E9.5) and bilaterally travel to the genital ridges to contribute to the formation of the gonads (E10.5-11.5)19,37. This process is complete by E33-37 in humans37,38.
Steel factor (KIT-ligand) has been identified as a key survival and proliferative signal for developing germ cells as well as acting to guide PGCs along the hindgut and towards the genital ridges39,40. The movement of PGCs out of the hindgut and into the gonads (E9.5) is dependent on E-cadherin (CDH1) and β1-integrin (ITGB1)37, and is directed by CXCL1241. On reaching the genital ridges at around E11 to E11.5, the PGCs proliferate and form gonocytes35. At this time, active demethylation continues by UTX (histone demethylase), another pluripotency factor, before the cells then undergo sex specific epigenetic changes required to produce viable germ cells25,42. By E13.5 the gonocytes enter either mitotic arrest in the case of testis, or meiotic arrest in the ovary. Therefore the period of time between the arrival in the gonad and arrest is key to the primordial germ cell proliferation and differentiation43.
Male sex determination is triggered by the expression of SRY (Sex-determining region on the Y chromosome), a high mobility group (HMG) transcription factor which activates SOX9 (SRY related HMG box 9), another transcription factor which in itself is sufficient for sex determination44,45. SOX9-positive pre-Sertoli cells recruit cells from the mesonephros and the coelomic epithelium to form the testicular cords46,47 which occurs in concert with the commitment of male germ cells to the pre-spermatogonia cell fate48. Sertoli cells also secrete paracrine factors (DHH and platelet-derived growth factors) initiating the differentiation of the testosterone producing Leydig cells49.
Male germ cells are maintained in mitotic arrest within the seminiferous tubules by the enzyme CYP26B1 which facilitates degradation of retinoic acid, preventing the expression of STRA8 (stimulated by retinoic acid 8) and hence entry into meiosis50. When the expression of CYP26B1 decreases at E13.5, the RNA binding protein NANOS2 maintains mitotic arrest in male germ cells51. Shortly after birth in mice, and in late gestation in humans, gonocytes (prospermatogonia) migrate from the centre to the basement membrane of the seminiferous tubules and by postnatal day 6 they have begun to divide and are designated single spermatogonia (As) or spermatogonial stem cells (SSCs) and spermatogenesis is initiated52.
Risk factors and genetic predisposition of testicular cancer
The risk factors for type II TGCTs include family predisposition, cryptorchidism, disorders of sexual development, high maternal oestrogen during foetal development, environmental exposures, sub- or infertility, and previous TGCTs3,36,53. Additionally, geographical regions with a high rate of TGCTs have lower sperm quality as well as increased rates of cryptorchidism and hypospadias when compared to regions with low rates of TGCTs54. While not all sexual development disorders lead to an increased risk of TGCTs, they usually occur at higher frequency in less differentiated gonads55. Identified genetic factors, including deletions on the Y chromosome, androgen insensitivity, and KIT mutations; negatively impact germ cell development supporting the notion that the risk of TGCTs is established early3,36,56. It is proposed that the combination of both genetic and environmental factors prevents or delays the maturation of PGCs/gonocytes into pre-spermatogonia by retarding the development of the supporting Sertoli and Leydig cells, thus perturbing the microenvironment required for germ cell development3,57.
Patients lacking the SRY gene on the Y chromosome required for Sertoli cell development, or WT1 required for ovary development, have a high risk of type II TGCTs, because of the lack of correctly differentiated support cells, which in turn inhibit germ cell development3. A partial deletion of the AZoospermia Factor C (AZFC) region (gr/gr mutation) on the short arm of the Y chromosome is also associated with an increased risk of TGCTs56.
Mutations in KIT signalling and continued KIT expression are seen in CIS cells, but not more advanced stages of testicular cancer, indicating that this may be an initial feature of CIS cell specification. Furthermore, genetic association studies have identified mutations in genes encoding KIT, KIT ligand and its downstream signalling molecules such as KRAS, SPRY4, and BAK1, as likely predisposition genes for TGCTs3,58–60. It is believed that a region of the Y chromosome encoding TSPY (testis specific protein Y-encoded), with a potential role in germ cell mitotic division, is required for the development of TGCTs. Interestingly, as with KIT, TPSY protein expression is lost when CIS becomes invasive36,55, suggesting that it may have a role in the initiation, but not maintenance, of tumours.
The switch to meiosis from mitotic amplification is tightly controlled in normal spermatogenesis and there is some indication that this pathway may be prematurely initiated then aborted in CIS and TGCTs61. Several members of the NOTCH signalling pathway control the mitotic to meiotic switch, and mutations in the NOTCH signalling pathway in C. elegans have been shown to elicit tumour-like expansion of germ cells61. This observation stimulated exploration of NOTCH signalling in human TGCTs and revealed that NOTCH1 and NOTCH4 are both over-expressed in CIS and seminoma. Additional genetic screening of affected individuals has identified mutations in members of the NOTCH family as primary risk factors for developing these pathologies61,62. The meiotic protein SYCP3, a component of the synaptonemal complex which aligns sister chromatids in prophase I of meiosis allowing their proper segregation, is also expressed in CIS, seminoma and embryonal carcinoma, thus providing further indication of a premature activation of meiosis in TGCTs development61.
More recent genetic screens have identified transcription factors DMRT1 and ATF7IP, as well as the telomere regulator TERT, as susceptibility genes for TGCTs58. DMTR1 is required for normal testicular differentiation and DMTR1 knockout mice have been shown to develop teratomas58. ATF7IP is a transcription factor that regulates the expression of subunits of the enzyme complex responsible for maintaining telomere length such as the active component, TERT63. Telomere regulation and length is tightly controlled within cells and usually only immortal cells, i.e. stem cells, express active telomerase. Telomerase is also extensively overexpressed in cancer cells and its activity plays a key role in the transformation process63,64.
However, in most cases no known genetic factor contributing to the development of TGCTs is identified and therefore environmental factors may play an essential role in the development of tumours in these individuals. The rates of TGCTs within Western countries have risen sharply since the early 1900s; however, this rise is not consistent across all countries8,65. The most notable differences in TGCT incidences and rates of increase are demonstrated in Europe. For example, increased TGCT rates were documented in England, Wales, and Germany before Denmark and Norway. By contrast, Finland, Eastern Germany, and Poland, still have lower TGCT rates than surrounding countries65,66. The rapid rise in TGCT rates, as well as the variation between geographical locations, implicates exposure to one or more environmental toxicants as a key risk factor65. For instance, it is believed that xeno-oestrogens and anti-testosterones negatively affect the development of Sertoli cells and Leydig cells causing a suboptimal environment for germ cell differentiation leading to reduced fertility and development of CIS cells3. Phthalates represent another possible environmental toxicant that could contribute to the incidence of TGCTs. Indeed, exposure to these toxins is known to be highly variable between different countries and this could, in part, contribute to geographical differences in cancer rates65. Additionally, high levels of phthalates have been documented in the blood of mothers whose sons developed TGCT6. Similarly, rats exposed to phthalates exhibit symptoms similar to testicular dysgenesis, which is also associated with a high risk of TGCT65. The possibility of toxicant exposure leading to TGCT has led to the investigation of detoxification mechanisms in cancer sufferers and their mothers56. While the power of this study is compromised by the small sample size, the analysis did demonstrate a link between specific cytochrome p450 polymorphisms and an increased rate of TGCT development56.
The development of type II testicular germ cell tumours
TGCTs originate from CIS cells, which are found on the basement membrane of abnormal seminiferous tubules that usually lack normal spermatogenesis. CIS cells were first identified in 1972 in biopsies of infertile men67, and a causal link was subsequently established when, during follow-up, the men with this lesion developed tumours while control subjects exhibited no cases of TGCT53. Furthermore, the incidence of CIS is about equal to that of type II TGCTs, suggesting that CIS cells will eventually develop into overt TGCT36.
Morphologically, CIS cells resemble primordial germ cells/gonocytes and express a number of similar markers, in that they lack imprinting and express OCT 3/4, PLAP and c-KIT36,68. In fact, the transcriptome of CIS cells is extremely similar to that of isolated normal human gonocytes, demonstrating a close relationship between these cell types16. CIS cells appear to be blocked from differentiating and entering spermatogenesis3. Instead they accumulate within the seminiferous tubule to become an intratubular lesion termed either seminoma or non-seminoma (embryonal carcinoma)3,36. Interestingly, seminomas can later reprogram to become non-seminomas36. These intratubular lesions proliferate to fill the lumen of the seminiferous tubule and rely on Sertoli cell-derived growth/survival signals and Leydig cell production of testosterone36. Once these cells break their dependence on external signals they become overt testicular cancer36.
Invasive TGCTs are characterised by a gain in copy number of the short arm of chromosome 123,53. Within this chromosomal region there are several genes encoding candidate virulence factors, including NANOG, KRAS2 and BCAT1; however, their role has yet to be confirmed3. BCAT1 for example, is only expressed in embryonal carcinoma and not in other germ cell lesions, indicating that the role of the genes on chromosome 12 may vary depending on the tumour type3. There are several markers which identify seminoma and non-seminoma tumours; for example, OCT 3/4 and NANOG are expressed in both seminoma and embryonal carcinoma, while SOX17 is specific to seminoma tumours and SOX2 is only expressed in non-seminoma69. In extended culture, ES cells gain excess copies of chromosome 12, but they do not seem to exhibit malignant characteristics, indicating that the gain of chromosome 12 is not the sole initiation factor for virulence in TGCTs3.
Possible mechanisms of germ cell cancer specification
Several risk factors have been identified in a mouse model of teratoma formation (strain 129/Ter)70. These include the continued expression of pluripotency markers and proliferation as well as premature differentiation, e.g. precocious entry into meiosis. Usually pluripotency factors such as NANOG, SOX2, and OCT 3/4, are down-regulated following cell cycle arrest at E13.5, but the germ cells of Ter mice continue to proliferate and express NANOG at E15.570. In this mouse model, PGCs also appear to prematurely differentiate with the detection of cyclin D1 as early as E13.570, compared to its normal expression in spermatogonia at postnatal day 471. It is possible that a similar mechanism occurs for the development of CIS cells considering that CIS cells express markers for primordial germ cells including PLAP, OCT 3/4, and c-KIT, long past embryonic development3. Concurrent with this delayed maturation is the expression of meiotic genes including NOTCH and SYCP3 in both CIS cells as well as seminoma cells61. Therefore maintenance of pluripotency in primordial germ cells while undergoing a defective maturation process, which may include premature activation of meiosis, could underpin the specification of these cells as CIS and tumorigenic (Figure 1).
Patients with stage I TGCTs and a concomitant high risk of metastasis are destined to undergo aggressive surgery and chemotherapy3. So far, vascular invasiveness, percentage of embryonal carcinoma and the proliferation index, have been the best predictors of metastasis risk. However, more recently the chemokine-mediated CXCR4 pathway has demonstrated some promise in metastasis prediction - with tumours containing localised high CXCL12 expression being less likely to metastasise3,72. Gilbert and colleagues72 examined TGCTs and found that seminomas expressed higher levels of CXCR4 transcript and protein, than normal testis, but this trend was not maintained in non-seminomas. In addition Gilbert et al.72 demonstrated that a seminoma cell line (TCam2) migrates in response to CXCL12α, via activation of the MAP kinase pathway. However, the non-seminoma cell line 2102EP does not, which is not surprising, as this cell line does not express CXCR4. We have independently looked at the expression of CXCL12 and CXCR4 in TGCTs (McIver SC, Loveland KL, Roman SD, Nixon B, Kitazawa R, McLaughlin EA, unpublished observations) and confirmed that CXCR4 mRNA was overexpressed in seminomas. However, at the protein level we did not find elevated levels of CXCR4 when its expression was examined via immunohistochemistry. Additionally, the tight correlation between CXCL12/CXCR4 with MAP kinase activation that is found in normal testis was abolished in the TGCT samples. We were able to confirm that both CXCL12α and β caused cell migration in the seminoma cell line (TCam2) while no migration response was observed in the CXCR4 positive non-seminoma cell lines 833ke and NTera2/D1. Therefore the expression of CXCL12 and CXCR4 is more likely to be a better indicator of the possibility of seminoma metastasis rather than non-seminoma.
Generally seminoma cells (a category that includes CIS cells) are extremely sensitive to irradiation as well as cisplatin-based chemotherapy drugs, while non-seminomas only respond to chemotherapy3. However, the mature teratoma components of non-seminoma tumours are resistant to DNA damage therapies, which is consistent with the loss of embryonal cell characteristics these tumour exhibit3. Although the common chemotherapy and radiotherapy treatments are very effective and maintain quality of life, they can lead to infertility, hypogonadism and retrograde ejaculation, which new treatment options should seek to avoid2,15. Both seminoma and non-seminoma tumours can become resistant to traditional oncology treatments3. Interestingly, evidence suggests that the methylation status of the cells DNA controls the expression of specific genes, such as c-FLAR, which inhibits caspase-dependant apoptosis, thus imparting resistance to cisplatin treatment3. Several other genes have been implicated in cisplatin resistance including Cyclin D13. Cyclin D1 is expressed in murine germ cells from post natal day 3, which coincides with the appearance of spermatogonia in testis and therefore may control the proliferation and differentiation of these cells71. The differentiation and abnormal proliferation of gonocytes is essential to the development of CIS, and therefore Cyclin D1 may play a key role in CIS evolution.
Role of miRNA in testicular germ cell tumours
A particularly exciting recent finding is that different types of TGCTs can be distinguished on the basis of their distinct miRNA expression profiles. For example, miR-122a is only expressed in yolk sac tumours69,73. Also the regulator of miRNA maturation, LIN28, has been shown to be expressed in PGCS, gonocytes and pre-spermatogonia CIS, seminoma and non-seminoma, where it regulates totipotency, and functions upstream of the tumour/pluripotency transcription factors OCT1/3 and NANOG31.
The tumour suppressor p53 generally controls the exit from the cell cycle upon DNA damage, to allow for either repair or apoptosis. It follows that p53 mutation is usually a key step in tumorigenesis; however, in TGCTs p53 is only rarely inactivated74. Voorhoeve et al.75 provided an explanation for this phenomenon when they determined that the presence of microRNAs; miR-372 and miR-373; conveyed a growth advantage and protected against the cellular senescence response to DNA damage, in the presence of wild type p53. Analysis of the molecular basis for this effect revealed that these miRNA molecules act in conjunction with RAS downstream of p53 in order to mimic the phenotype of inactivated p5375. Furthermore, the authors identified LATS2 (Large tumour suppressor homology 2) as a potential target of p53 signalling given that LATS2 deletion accelerates cellular proliferation and tumour development. This can be phenocopied in some seminomas, which do not overexpress miR-372 or miR-373, by mutations in LATS2. The LATS2 protein inhibits cyclin E/CDK2 activity and thereby arrests the cell cycle75. Later studies found that this miRNA cluster is exclusively over expressed in almost all seminomas and most embryonal carcinoma tumours74.
In addition to their role in the tumorigenesis of TGCTs, miRNAs have an essential role in the development of primordial germ cells and in spermatogenesis76. Therefore we decided to examine the change in the miRNA expression profile between postnatal gonocytes and spermatogonia in mice in the hope of gaining a better understanding of this essential step in both normal spermatogenesis and CIS development. This approach led to the identification of seven differentially expressed miRNA molecules (three of which were up regulated; miR-136, -743a and -463*, and four down regulated miR290-5p, -291a-5p, -294* and -293) during this developmental phase. Analysis of their potential targets indicated that these miRNA molecules were likely to impact the PTEN and Wnt/β catenin signalling pathways77 as well as the CXCR4 signalling pathway previously implicated in TGCT metastasis (McIver SC, Loveland KL, Roman SD, Nixon B, Kitazawa R, McLaughlin EA, unpublished observations). The PTEN tumour suppressor is known to inhibit PI3K signalling to negatively regulate cell growth and therefore its suppression causes increased proliferation and potentially tumourigenesis. The loss of PTEN is also associated with the transformation of CIS cells into overt cancerous tumours78. Furthermore, increased relapse rate in TGCTs has also been found to be associated with the loss of PIK3IP1, an additional negative regulator of PIK kinase79. Both the PTEN and Wnt/β catenin pathways converge to control the function of Cyclin D1, which is expressed in highly proliferative TGCTs where down-regulation instigates cell cycle arrest80, and is associated with chemotherapy resistance in these tumours3. Indeed, on this basis, the control of Cyclin D1 activity has been suggested as a potential treatment target80. Subsequently we selected the three most highly differentially expressed miRNA (Mir-743a, -291a-5p, -293) and instigated a strategy to directly identify their targets. The use of a pull down approach pioneered by Orum and Lund81 in which the miRNAs were used as bait, and bound mRNA analysed by microarray, revealed a significant number of predicted and non-predicted targets bound to each miRNA (McIver SC, Roman SD, Nixon B, McLaughlin EA., unpublished observations).
Interestingly the targets identified were postulated to regulate key germ cell migration and proliferation pathways controlled through PDGF82 and RAC83 signalling (McIver SC, Roman SD, Nixon B, McLaughlin EA, unpublished observations). PDGF signalling is known to play a role in gonocyte migration and proliferation82,84. In addition, PDGF signalling has been shown to work in conjunction with oestrogen signalling84, a mechanism that is easily hijacked by the presence of xeno-oestrogens. In fact gonocytes have been shown to be more sensitive to xeno-oestrogens than endogenous ligands84. This has implications for the development of CIS because high concentrations of xeno-oestrogens are associated with increased TGCT risk3. RAC on the other hand has been shown to be essential for the transmigration of spermatogonial stem cells through the blood-testis barrier during testis colonisation assays83. Using a knockdown assay as an alternate technique to determine the targets of miR-291a-5p, -293 and -743a we identified one promising gene, IGFBP7 (Insulin-like growth factor binding protein 7) (McIver SC, Roman SD, Nixon B, McLaughlin E A, unpublished observations), which is known to act as either a positive (e.g. in glioma85) or negative regulator (e.g. in breast and liver cancer86,87) of cell proliferation and migration depending on the environment in which it is found. Therefore the disrupted expression of IGFBP7 by aberrantly expressed miRNAs during the gonocyte to spermatogonia transition could have implications for their growth and differentiation.
The miRNA molecules found to be down regulated during gonocyte differentiation into spermatogonia all belong to the miR-290 family. This cluster of miRNA is highly expressed in embryonic stem cells (ES) and is known to be a key regulator of ES cell pluripotency, controlling the expression of OCT4, SOX2 and NANOG88–90. Additionally, upon knockout of the miR-290 cluster, aberrant migration of germ cells has been observed with significantly fewer primordial germ cells reaching the bipotential gonad88. Comparatively less is known about the miRNA molecules that were found to be upregulated during gonocytes differentiation. miR-136 is proposed to be a tumour suppressor in glioma and is capable of targeting the anti-apoptosis genes AEG-1 and BCL-291. miR-743a on the other hand is involved in oxidative stress responses92. On the basis of these data, as well as our own observations of miRNA involvement in key germ cell regulatory pathways77, it appears likely that the changing miRNA profile between postnatal gonocytes and spermatogonia could have a fundamental role in the development of CIS within the testis.
Research into both the genetic and environmental factors that predispose an individual to type II TGCTs has been hampered by the lack of a suitable animal model for the study this tumour type. Mouse models are suitable for the study of type I neonatal TGCTs and canines exhibit type III TGCTs caused by an expansion of type B spermatogonia. These models offer a number of advantages in terms of allowing genetic screens and treatments to be conducted to enhance our understanding of these cell types36. In contrast, the study of seminoma and non-seminoma tumours is restricted to cell lines and, in the case of seminoma, these are scarce36, severely limiting explorative experiments to study these tumour types. Type II TGCTs have been extensively characterised at the molecular level resulting in the identification of several predisposition genes, tumour markers, as well as the mode of tumour progression3. However, despite our extensive knowledge of mature tumours, the exact triggers for the development of CIS cells remain unknown. Unfortunately, until these mechanisms are identified, therapeutic interventions are limited. Current treatment techniques are very effective but their side effects often include a loss of fertility, a concerning fact given that these tumours primarily arise in men of reproductive age15. Therefore, a better understanding of the cellular mechanisms underlying germ cell development, are vital to establish novel treatments that are capable of preserving fertility in patients.
Open Peer Review
Current Referee Status:
Key to Referee Statuses
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservationsKey revisions are required to address specific details and make the paper fully scientifically sound
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions
Read more about the unique F1000Research publication and peer review model here.
Competing Interests Policy
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
- Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.
- You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.
- You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).
- You work at the same institute as any of the authors.
- You hope/expect to benefit (e.g. favour or employment) as a result of your submission.
- You are an Editor for the journal in which the article is published.
- You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.
- You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.
- You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.